The year 2022 marks ten years since the publication of the landmark study by Jennifer Doudna and her colleagues that pointed to a new revolutionary method for editing DNA. Today, CRISPR — and its associated gene-editing techniques — is one of the most well-known tools of synthetic biology and has paved the way for new advancements in this field. Synthetic biology has made great strides since CEP last published a special section on this topic in September 2016.
This special section takes an in-depth look at some of the companies innovating in the synthetic biology space, and discusses what will need to happen to maintain the talent pipeline for this industry to further spearhead such discoveries. Many of the articles in this special section are based on presentations given at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, hosted by the Society of Biological Engineering (SBE) in May 2022.
The first article in the special section (pp. 24–29), written by Matthew Lipscomb, describes the technology being commercialized by DMC Biotechnologies. Their Dynamic Metabolic Control (DMC) platform...
Would you like to access the complete CEP Article?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
AIChE Membership
You must be an AIChE member to view this article. Join now.
Copyright Permissions
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.